The off-label use of JAK inhibitors to treat JDM is common in pediatric rheumatology, with barriers to use including limited clinical trial data and insurance approval.

If you experience persistent muscle weakness, fatigue and skin changes that don't seem to fade, it could be more than just everyday exhaustion. These lingering issues may be symptoms of ...

Several known risk factors of Dermatomyositis (DM ... She is recognized for her contributions to advancing treatment options and understanding of these challenging conditions.

The drug – called brepocitinib – is the centrepiece of the new biotech's R&D pipeline and is already a pair of pivotal trials in patients with dermatomyositis and systemic lupus erythematosus ...